Under the agreement, the Company received initial funding at closing, with future tranches available upon achieving certain milestones. The financing is intended to support the scale-up of the Company’s proprietary laboratory-developed tests, particularly its CNSide® cerebrospinal fluid ("CSF") assay platform.

"Cerenome is grateful for the support of the 3i Fund team, and we look forward to a long-term relationship," said Andrew Sims, Cerenome’s Chief Financial Officer. "This facility is designed to be minimally dilutive to stockholders while supporting the next stage of commercial scale-up and development of CNSide, specifically growing sales and broadening the pipeline. We forecast our cash runway is now well into 2028 when we consider, the 3i facility, other existing facilities along with current cash and forecasted CNSide related sales and cash flow."

Additional transaction details are included in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.